# Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy

> **NCT02569723** · NA · COMPLETED · sponsor: **Edward Kim** · enrollment: 6 (actual)

## Conditions studied

- Colon Adenocarcinoma

## Interventions

- **DRUG:** Carbon C 14 Oxaliplatin
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT02569723
- **Lead sponsor:** Edward Kim
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-16
- **Primary completion:** 2018-04-20
- **Final completion:** 2020-04-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02569723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02569723, "Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02569723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*